Pub Date : 2023-04-07DOI: 10.21911/aai.057AsthmaAllergyImmunol2022
O. Ozdemir, Ummugulsum Dikici, Olena Erkun
Messenger RNA (mRNA) vaccines have long been suggested as encouraging candidates for widespread vaccination since they are manufactured rapidly and induce both humoral and cellular immune system components against pathogens. Available data on the efficacy and safety of these vaccines are relatively limited and the spectrum of skin reactions is still unclear. We would like to contribute to the literature by presenting a rare case with cutaneous reactions and discussing the skin complications of these kinds of vaccines. Our patient was a 17-year-old healthy female patient who applied to the pediatric emergency department with urticarial plaques that started from the legs and spread to the trunk nearly 80 hours after the second dose of the BioNTech-Pfizer COVID-19 vaccine was applied. The patient, whose skin lesions recurred more severely within 24 hours at home, and who noticed mild swelling in the fingers of the right hand and on the lip, was brought to the emergency service for the second time. Patients and physicians should be aware of the risk of delayed adverse skin reactions as well as the development of immediate hypersensitivity reactions such as urticaria and angioedema after administration of an mRNA COVID-19 vaccine.
{"title":"Delayed Urticaria- Angioedema After mRNA Vaccine in an Adolescent Patient: Case Report","authors":"O. Ozdemir, Ummugulsum Dikici, Olena Erkun","doi":"10.21911/aai.057AsthmaAllergyImmunol2022","DOIUrl":"https://doi.org/10.21911/aai.057AsthmaAllergyImmunol2022","url":null,"abstract":"Messenger RNA (mRNA) vaccines have long been suggested as encouraging candidates for widespread vaccination since they are manufactured rapidly and induce both humoral and cellular immune system components against pathogens. Available data on the efficacy and safety of these vaccines are relatively limited and the spectrum of skin reactions is still unclear. We would like to contribute to the literature by presenting a rare case with cutaneous reactions and discussing the skin complications of these kinds of vaccines. Our patient was a 17-year-old healthy female patient who applied to the pediatric emergency department with urticarial plaques that started from the legs and spread to the trunk nearly 80 hours after the second dose of the BioNTech-Pfizer COVID-19 vaccine was applied. The patient, whose skin lesions recurred more severely within 24 hours at home, and who noticed mild swelling in the fingers of the right hand and on the lip, was brought to the emergency service for the second time. Patients and physicians should be aware of the risk of delayed adverse skin reactions as well as the development of immediate hypersensitivity reactions such as urticaria and angioedema after administration of an mRNA COVID-19 vaccine.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41741527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Delayed Urticaria- Angioedema After mRNA Vaccine in an Adolescent Patient: Case Report","authors":"Oner OZDEMIR, Ummugulsum DIKICI, Olena ERKUN","doi":"10.21911/aai.057","DOIUrl":"https://doi.org/10.21911/aai.057","url":null,"abstract":"","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135792786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Father and Son Diagnosed with DiGeorge Syndrome","authors":"Murat Ozer, C. Aytekin","doi":"10.21911/aai.044","DOIUrl":"https://doi.org/10.21911/aai.044","url":null,"abstract":"","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41896872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: With the approval of the use of COVID-19 vaccines for children, their administration has started in many countries. However, families have some hesitations about vaccinating their children with the COVID-19 vaccines. The aim of this study was to determine the COVID-19 vaccination rates in allergic children aged 12-19 years and to evaluate contributing factors to vaccine hesitation. Materials and Methods: This cross sectional study was carried out in a Pediatric Allergy Department of a university-affiliated hospital between 15th December 2021 and 15th February 2022. Parents of allergic children who agreed to participate in this study constituted the study population (n=261).Results: Of the 261 children with allergic diseases, 137 (52.4%) had two doses of the COVID-19 vaccine, and 89.3% of the mothers and 92.3% of the fathers had at least two doses of the COVID-19 vaccine. Among children who were not vaccinated (n=124), the leading reason was the novelty of the vaccine, and the second reason was the side effects. The perceived stress scale score of the parents in the vaccinated group was significantly (p <0.05) higher than in the unvaccinated group.Conclusion: Although there is an effective and safe vaccine for children during the pandemic, vaccination rates are not yet at the desired level.
{"title":"Allergic Children’s Parents’ Hesitancy About COVID-19 Vaccination","authors":"Pınar Yılmazbaş, D. Ozceker","doi":"10.21911/aai.013","DOIUrl":"https://doi.org/10.21911/aai.013","url":null,"abstract":"Objective: With the approval of the use of COVID-19 vaccines for children, their administration has started in many countries. However, families have some hesitations about vaccinating their children with the COVID-19 vaccines. The aim of this study was to determine the COVID-19 vaccination rates in allergic children aged 12-19 years and to evaluate contributing factors to vaccine hesitation. Materials and Methods: This cross sectional study was carried out in a Pediatric Allergy Department of a university-affiliated hospital between 15th December 2021 and 15th February 2022. Parents of allergic children who agreed to participate in this study constituted the study population (n=261).Results: Of the 261 children with allergic diseases, 137 (52.4%) had two doses of the COVID-19 vaccine, and 89.3% of the mothers and 92.3% of the fathers had at least two doses of the COVID-19 vaccine. Among children who were not vaccinated (n=124), the leading reason was the novelty of the vaccine, and the second reason was the side effects. The perceived stress scale score of the parents in the vaccinated group was significantly (p <0.05) higher than in the unvaccinated group.Conclusion: Although there is an effective and safe vaccine for children during the pandemic, vaccination rates are not yet at the desired level.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48786100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ş. Beyaz, Neyran Serbetci, Zeynep Turkan Fendoglu, E. Bulbul, Zeynep Hancıoğlu, Dilek OKSUZER CIMSIR, Ozge OZTURK AKTAS, Zeynep Celebi Sozener, Sadan Soyyigit
Objective: Although the factors that trigger and exacerbate chronic spontaneous urticaria (CSU) are well known, there is still a lack of information about the effects of COVID-19 vaccines on CSU. This study aimed to investigate exacerbations/relapses triggered by COVID-19 vaccines in patients with CSU who are well controlled with treatment or in remission. Materials and Methods: The study included 350 CSU patients. Demographic and clinical characteristics were collected from patients' medical records. The seven-day urticaria activity score (UAS7) and urticaria control test (UCT) were evaluated separately during the onset of the disease, pre-vaccination, and post-vaccination periods. Results: The mean age was 39.89 +/- 13.30 years and 74.6% of the patients were female. A total of 227 patients were vaccinated with the Pfizer/BioNTech mRNA vaccine, 67 with the Sinovac/CoronaVac inactivated vaccine, and 54 with both vaccines. Urticaria exacerbations/ relapses were observed in a total of 76 patients, and most CSU exacerbations/relapses occurred after the first dose (n=46). Median UAS7 scores increased significantly in the post-vaccination period in patients who experienced urticaria exacerbation (p<0.0001). Median UCT scores were significantly decreased due to urticaria exacerbation with vaccination (p<0.0001). Conclusion: Both mRNA and inactivated COVID-19 vaccine may lead to exacerbations or relapses in patients with CSU. Even so, exacerbations/relapses associated with COVID-19 vaccines can be easily controlled with treatments and do not preclude subsequent doses.
{"title":"The Impact of Vaccination with SARS-CoV-2 Vaccines on the Course of Chronic Spontaneous Urticaria","authors":"Ş. Beyaz, Neyran Serbetci, Zeynep Turkan Fendoglu, E. Bulbul, Zeynep Hancıoğlu, Dilek OKSUZER CIMSIR, Ozge OZTURK AKTAS, Zeynep Celebi Sozener, Sadan Soyyigit","doi":"10.21911/aai.083","DOIUrl":"https://doi.org/10.21911/aai.083","url":null,"abstract":"Objective: Although the factors that trigger and exacerbate chronic spontaneous urticaria (CSU) are well known, there is still a lack of information about the effects of COVID-19 vaccines on CSU. This study aimed to investigate exacerbations/relapses triggered by COVID-19 vaccines in patients with CSU who are well controlled with treatment or in remission. Materials and Methods: The study included 350 CSU patients. Demographic and clinical characteristics were collected from patients' medical records. The seven-day urticaria activity score (UAS7) and urticaria control test (UCT) were evaluated separately during the onset of the disease, pre-vaccination, and post-vaccination periods. Results: The mean age was 39.89 +/- 13.30 years and 74.6% of the patients were female. A total of 227 patients were vaccinated with the Pfizer/BioNTech mRNA vaccine, 67 with the Sinovac/CoronaVac inactivated vaccine, and 54 with both vaccines. Urticaria exacerbations/ relapses were observed in a total of 76 patients, and most CSU exacerbations/relapses occurred after the first dose (n=46). Median UAS7 scores increased significantly in the post-vaccination period in patients who experienced urticaria exacerbation (p<0.0001). Median UCT scores were significantly decreased due to urticaria exacerbation with vaccination (p<0.0001). Conclusion: Both mRNA and inactivated COVID-19 vaccine may lead to exacerbations or relapses in patients with CSU. Even so, exacerbations/relapses associated with COVID-19 vaccines can be easily controlled with treatments and do not preclude subsequent doses.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48338466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cansu Ozdemiral, S. Esenboğa, Hacer Neslihan Bildik, D. Çağdaş, I. Tezcan
{"title":"Hyper IgM Syndrome with a Novel Mutation in the AICDA Gene: Easy to Diagnose","authors":"Cansu Ozdemiral, S. Esenboğa, Hacer Neslihan Bildik, D. Çağdaş, I. Tezcan","doi":"10.21911/aai.073","DOIUrl":"https://doi.org/10.21911/aai.073","url":null,"abstract":"","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48696893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. Tuncay, Ozge Can Bostan, M. Çakmak, S. B. Kaya, E. Damadoğlu, G. Karakaya, A. Kalyoncu
{"title":"Successful Desensitization in a Patient with Fabry Disease with Agalsidase Beta Anaphylaxis: A Rare Case Report","authors":"G. Tuncay, Ozge Can Bostan, M. Çakmak, S. B. Kaya, E. Damadoğlu, G. Karakaya, A. Kalyoncu","doi":"10.21911/aai.052","DOIUrl":"https://doi.org/10.21911/aai.052","url":null,"abstract":"","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48788950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I. Turan, M. H. Celiksoy, Sezin Naiboğlu, S. Ulaş, Ç. Aydoğmuş
{"title":"DRESS Syndrome due to Carbamazepine Use in A Drug-Addicted Adolescent","authors":"I. Turan, M. H. Celiksoy, Sezin Naiboğlu, S. Ulaş, Ç. Aydoğmuş","doi":"10.21911/aai.004","DOIUrl":"https://doi.org/10.21911/aai.004","url":null,"abstract":"","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42769167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Identification of Novel Endochitinase Class I Based Allergens","authors":"Levent Çavaş, Yesim YILMAZ-ABESKA","doi":"10.21911/aai.065","DOIUrl":"https://doi.org/10.21911/aai.065","url":null,"abstract":"","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44840719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：